A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers

BACKGROUND: Tenapanor (RDX5791, AZD1722), a small molecule with minimal systemic availability, is an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3). Tenapanor acts locally in the gut to reduce absorption of sodium and phosphate. It is being developed for the treatment of patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Susanne, Rosenbaum, David P., Knutsson, Mikael, Leonsson-Zachrisson, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486465/
https://www.ncbi.nlm.nih.gov/pubmed/27368672
http://dx.doi.org/10.1007/s10157-016-1302-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486465/
https://www.ncbi.nlm.nih.gov/pubmed/27368672
http://dx.doi.org/10.1007/s10157-016-1302-8

Ejemplares similares